Versor Investments LP Invests $505,000 in Enovis Corporation $ENOV

Versor Investments LP bought a new position in Enovis Corporation (NYSE:ENOV) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 16,100 shares of the company’s stock, valued at approximately $505,000.

Several other institutional investors and hedge funds also recently modified their holdings of ENOV. Humankind Investments LLC boosted its holdings in Enovis by 8.6% in the 1st quarter. Humankind Investments LLC now owns 5,688 shares of the company’s stock worth $217,000 after acquiring an additional 452 shares during the period. US Bancorp DE boosted its stake in shares of Enovis by 2.5% in the first quarter. US Bancorp DE now owns 19,031 shares of the company’s stock valued at $727,000 after purchasing an additional 462 shares during the period. Leisure Capital Management boosted its stake in shares of Enovis by 2.2% in the first quarter. Leisure Capital Management now owns 22,903 shares of the company’s stock valued at $875,000 after purchasing an additional 489 shares during the period. Teacher Retirement System of Texas boosted its stake in shares of Enovis by 6.1% in the second quarter. Teacher Retirement System of Texas now owns 8,664 shares of the company’s stock valued at $272,000 after purchasing an additional 495 shares during the period. Finally, Wedge Capital Management L L P NC boosted its stake in shares of Enovis by 0.3% in the second quarter. Wedge Capital Management L L P NC now owns 162,977 shares of the company’s stock valued at $5,111,000 after purchasing an additional 498 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Stock Performance

Shares of ENOV stock opened at $31.52 on Wednesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.15 and a current ratio of 2.25. Enovis Corporation has a one year low of $25.47 and a one year high of $49.83. The company’s 50-day simple moving average is $31.42 and its 200-day simple moving average is $31.53. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of -2.21 and a beta of 1.69.

Enovis (NYSE:ENOV) last released its earnings results on Monday, January 8th. The company reported $0.59 EPS for the quarter. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The company had revenue of $383.81 million for the quarter. Equities analysts anticipate that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Phillip Benjamin (Ben) Berry acquired 2,500 shares of Enovis stock in a transaction that occurred on Wednesday, August 20th. The shares were purchased at an average cost of $29.71 per share, for a total transaction of $74,275.00. Following the completion of the purchase, the chief financial officer directly owned 116,729 shares of the company’s stock, valued at $3,468,018.59. This trade represents a 2.19% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Damien Mcdonald acquired 6,457 shares of Enovis stock in a transaction that occurred on Thursday, September 11th. The shares were purchased at an average price of $30.97 per share, for a total transaction of $199,973.29. Following the completion of the purchase, the chief executive officer directly owned 102,753 shares of the company’s stock, valued at $3,182,260.41. The trade was a 6.71% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 12,157 shares of company stock worth $374,760 over the last ninety days. 2.70% of the stock is owned by insiders.

Analysts Set New Price Targets

ENOV has been the subject of a number of analyst reports. Evercore ISI decreased their price objective on shares of Enovis from $48.00 to $46.00 and set an “outperform” rating for the company in a research report on Tuesday, July 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enovis in a report on Wednesday, October 8th. UBS Group reduced their price target on Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a report on Friday, August 8th. Wells Fargo & Company reduced their target price on Enovis from $48.00 to $41.00 and set an “overweight” rating for the company in a research note on Friday, August 8th. Finally, Needham & Company LLC reduced their target price on Enovis from $57.00 to $49.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $51.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.